The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Parsaclisib for MCL: next steps?
Amitkumar Mehta, MD, UAB School of Medicine, Birmingham, AL, discusses future research based on results from the CITADEL-205 (NCT03235544) Phase II study which aimed to evaluate the efficacy and safety of parsaclisib monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients. Dr Mehta discusses the prospect of combining parsaclisib with other therapies for indolent and aggressive MCL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
